ACM
DNTH icon

Asymmetry Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

Asymmetry Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-13,191
Closed -$1.58M – 39
2020
Q2 		$1.58M Buy
+13,191
New +$1.86M 1.21% 23

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Asymmetry Capital Management's DNTH Position: Q3 2020 in Review

Asymmetry Capital Management sold out of Dianthus Therapeutics (DNTH) in Q3 2020, closing a stake of 13,191 shares — an estimated $1.58M sold.

Asymmetry Capital Management first reported a position in DNTH in Q2 2020 and held it in 1 quarter. The position peaked at $1.58M in Q2 2020. 94 funds tracked by Wall St. Rank hold DNTH as of Q3 2020.

  • Asymmetry Capital Management reported no remaining Dianthus Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Asymmetry Capital Management sold 13,191 Dianthus Therapeutics shares in Q3 2020, an estimated $1.58M.
  • Asymmetry Capital Management first reported a position in Dianthus Therapeutics in Q2 2020 and held it in 1 quarter.
  • Asymmetry Capital Management's Dianthus Therapeutics position peaked at $1.58M in Q2 2020.
  • 94 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2020.

Based on Asymmetry Capital Management's 13F filing for Q3 2020, filed 12 Nov 2020.